ArticleProceedings (Baylor University. Medical Center)2026
Hormonal therapy and cardiovascular risk in polycystic ovary syndrome: a propensity-matched cohort study.
Article in Proceedings (Baylor University. Medical Center), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPolycystic ovary syndrome (PCOS) is associated with increased cardiovascular disease risk. Hormonal therapy is a cornerstone of PCOS management, yet its long-term cardiovascular safety remains uncertain.
methodsThis retrospective cohort study using TriNetX included adult women with PCOS stratified by hormonal therapy initiation within 1 month of diagnosis versus never receiving therapy. One-to-one propensity score matching was performed. The primary outcome was major adverse cardiovascular events (MACE). Cox proportional hazards models estimated hazard ratios (HRs).
resultsAfter matching, 104,849 patients were included per cohort. Over 1-year follow-up, hormonal therapy was associated with a lower risk of MACE (hazard ratio [HR] 0.72; 95% confidence interval 0.62-0.83), all-cause mortality (HR 0.68; 0.57-0.80), hospitalization (HR 0.55; 0.54-0.57), and atrial fibrillation (HR 0.76; 0.62-0.94) (all
conclusionsHormonal therapy in PCOS was associated with reduced MACE, mortality, and hospitalization without increased thrombotic or arrhythmic risk, supporting cardiovascular safety and potential cardioprotective effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.